Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Juliet K. Choi, executive vice president and chief of staff of the Asian & Pacific Islander American Health Forum (APIAHF), a national health justice organization which influences policy, mobilizes communities, and strengthens programs and organizations to improve the health of Asian Americans, Native Hawaiians and Pacific Islanders.
May is Asian American and Pacific Islander Heritage Month, a time to commemorate the contributions that people of Asian American, Native Hawaiian and Pacific Islander (AA & NHPI) descent have had on our nation’s shared culture and history while rooting us in the present and looking ahead to the future.
This year’s Asian American and Pacific Islander Heritage Month carries a different weight for many in AA & NHPI communities as our nation grapples with the COVID-19 pandemic. COVID-19 has laid bare the disproportionate impact on our most vulnerable that stem from longstanding inequities. In the 11 weeks since the World Health Organization declared the pandemic my organization, The Asian & Pacific Islander American Health Forum (APIAHF), has rapidly responded, recognizing that these inequities threaten our collective response and health of AAs & NHPIs.
Due to existing health disparities and systemic barriers, including higher prevalence of chronic health conditions and barriers to health care, minority and immigrant populations are more at-risk of severe illness from COVID-19. Best available data from multiple states and municipalities indicate that AAs have a case fatality rate that is disproportionately higher than the general population. This could be because AAs are not getting access to testing or are more likely to die once infected, or both. And if we dig deeper, we know that AAs & NHPIs experience significant health disparities. When compared with non-Hispanic whites, AAs & NHPIs are more likely to develop tuberculosis, Hepatitis B and Cancer. Infrequent medical screenings and visits, lack of medical insurance, as well as limited English proficiency are all common barriers to healthcare for AAs & NHPIs.
This is why we at APIAHF have been working with national, state and local advocates to call for disaggregated demographic data on individuals with COVID-19. Because we need much more detailed information to better understand the impact of COVID-19 on AAs, NHPIs and other communities of color.
At the same time, legal, systemic and socio-economic factors impact AA & NHPI health and response to COVID-19. For example, access to health insurance coverage is uneven with millions of immigrants ineligible for Medicaid and other public insurance programs. That is a major challenge for the 60% of AAs who are immigrants and span every immigration status. This is why APIAHF is working with advocates nationwide to ensure that any congressional response includes testing and treatment for COVID-19 for all, no matter their immigration status.
Non-COVID-19 patients fluent in English struggle to communicate with their providers about how to control existing conditions, reschedule appointments and reduce their risk of becoming infected. Therefore, it is paramount that the 25 million Limited English Proficient (LEP) Americans receive linguistically appropriate services to address their COVID-19 and non-COVID related health needs. Our organization continues to emphasize the critical importance of including comprehensive language access in Congressional relief packages during this challenging time. And we have heard reports from our partners about what happens when language assistance is not available or provided to LEP persons. For example, we recently talked to the daughter of a woman in a Seattle hospital who is LEP and had COVID-19. She progressed to a point where she needed to be intubated, but the hospital did not make an interpreter available when making that decision. This woman faced an incredibly invasive procedure without having the opportunity, really the right, to understand what was happening to her in her preferred language.
Over 2 million AA & NHPI essential workers in health care, transportation and service industries face increased exposure to COVID-19. Unfortunately, Asian Americans on the frontline, who represent 18% of the country’s physicians, 10% of the nurse practitioners and 22% of pharmacists have been subjected to targeted racism and violence. APIAHF along with nine leading civil rights organizations believe that greater cultural competency and unification efforts are needed to stop COVID-19 related prejudice and discrimination in its tracks.
We all have a unique role to play in combatting this harrowing pandemic. As the biopharmaceutical industry races to develop a vaccine and treatments at a record pace, our organization, together with our network of community partners, is doing our part by providing in-language COVID-19 resources to AA & NHPI communities while advocating for inclusive federal public health and economic relief. As summer approaches, our role as citizens to continue compliance with physical distancing practices is vital to slowing the spread of the virus and ensuring the safety of our most at-risk populations.
To commemorate this year’s Asian American and Pacific Islander Heritage Month, we can and must all work together to tackle one of the greatest public health crisis in modern history. Community and shared partnerships is how we have weathered tough times in the past and it’s the only way forward. Together, we can protect the health and well-being of all communities.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
WHO Pandemic Agreement offers opportunities and risks for American innovators
What you should know about protecting your health this fall
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
Key considerations as Congress works towards PAHPA reauthorization
A conversation with Dr. Mike Ybarra on the current state of COVID-19
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Celebrating the success of the COVID-19 vaccines, and looking to the future
PhRMA submits comments to OSTP on enhancing clinical trial diversity
What we’ve learned from three years of fighting COVID-19
U.S. must address IP and market access barriers abroad to protect American innovation
Word of the Month: What is TRIPS?
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
A conversation with Barry Greene, CEO of Sage Therapeutics
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
Protecting U.S. innovation abroad to support economic and pandemic recovery
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
Navigating the patient experience in the time of COVID-19
Global COVID-19 vaccination matters now and for the future
Understanding breakthrough COVID-19 infections
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
The important role of antivirals in the fight against COVID-19
Understanding Long COVID-19
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
The impact of monoclonal antibodies and COVID-19 recovery
Recognizing National Immunization Awareness Month
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
PhRMA awards $75,000 to fund initiatives to reduce health inequities
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Americans 12 years of age and older are eligible for COVID-19 vaccines
PhRMA hosts first stakeholder workshop on clinical trial diversity
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
A year later: Reflections on the meaning of equity
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
Reflecting on Mental Health Awareness Month
American leadership on innovation policy is essential to global health progress
Patient safety is at the heart of COVID-19 vaccine R&D
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
Diversifying clinical trials and fighting disease requires equity and trust
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
Top five issues voters want addressed in the administration’s first 100 days
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Lessons learned from COVID-19: The way we develop new medicines is changing
Growing trend: Increased vaccine confidence
Election insights: Common ground areas to address Americans’ health care concerns
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Election insights: Voter priorities in the states
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Insights from the election: Meeting voters where they are on health care
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Guest Post: Bringing our best to the fight against COVID-19
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Deep dive: The issues that drove the 2020 vote
Understanding the emergency use authorization process for COVID-19 vaccines
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
Voters want to address the real drivers of health care costs for patients and the system
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
The 2020 We Work for Health Champion Awards showcase the best of our industry
Summer reading in the age of COVID-19
The patient perspective navigating COVID-19
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
Executive order threatens R&D when we need it most to fight COVID-19
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
New initiative to bridge the gap on antimicrobial innovation
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest post: A post-pandemic crisis: The mental toll on America
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
PhRMA awards $100,000 to fund projects that address health inequalities
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
What scientific experts are saying about vaccine safety
IP Explained: Intellectual property system working to combat COVID-19
Guest Post: What will we learn from COVID-19?
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
Guest Post: Preserving clinical research sites during the coronavirus pandemic
Observing National Minority Health Month in the age of COVID-19
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
Guest post: Securing the health care supply chain during COVID-19
To the millions affected by COVID-19
New infographic: How we are fighting COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Helping those affected by the coronavirus
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
Coronavirus
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19